Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Locally Advanced Breast Cancer (LABC) 1Liver Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 20Cisplatin 17Cetuximab 13Docetaxel 11Paclitaxel 9Carboplatin 9Radiotherapy 8Fluorouracil 6cemiplimab 5130-nm albumin-bound paclitaxel 5Bleomycin 4Radiation 3Pemetrexed 3Panitumumab 3Nivolumab 3Gemcitabine 3Albumin-Bound Paclitaxel 3vandetanib 2talimogene laherparepvec 2selinexor 2motexafin gadolinium 2figitumumab 2brigatinib 2avelumab 2atezolizumab 2alpha-2'-deoxythioguanosine 2advexin 2Taxes 2ON 01910 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Squamous Cell × advexin × Clear all
NCT00041613 2008-04-01

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT00041626 2007-09-11

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡